Top-News
Pharmazeutika USA

Inovio Pharmaceuticals News

Aktie
WKN:  A400EJ ISIN:  US45773H4092 US-Symbol:  INO
10,12 €
+0,00 €
0,00%
16:38:22 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
1,82 Mio.
Marktkapitalisierung *
18,49 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.01.2024

Inovio Pharmaceuticals News

07.09.23 - PR Newswire
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis PR Newswire
01.09.23 - Gurupress
Inovio Quartalsbilanz in 65 Tagen: Analysten erwarten Umsatzrückgang und Gewinnentwicklung
In 65 Tagen wird das Unternehmen Inovio aus Plymouth Meeting, Vereinigte Staaten, seine Quartalsbilanz für das 3. Quartal dieses Jahres vorlegen. Aktionäre sind gespannt auf ...
29.08.23 - PR Newswire
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire
09.08.23 - PR Newswire
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update PR Newswire
04.08.23 - PR Newswire
INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire
26.07.23 - PR Newswire
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023 PR Newswire
23.06.23 - GlobeNewswire
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) --
25.05.23 - PR Newswire
INOVIO to Present at the 2023 Jefferies Healthcare Conference
INOVIO to Present at the 2023 Jefferies Healthcare Conference PR Newswire
23.05.23 - PR Newswire
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission PR Newswire
10.05.23 - PR Newswire
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights PR Newswire
08.05.23 - PR Newswire
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023 PR Newswire
05.05.23 - PR Newswire
INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference PR Newswire
28.04.23 - PR Newswire
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023 PR Newswire
27.04.23 - PR Newswire
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023 PR Newswire
26.04.23 - PR Newswire
European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107
European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107 PR Newswire
17.04.23 - PR Newswire
Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023
Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-​ZEBOV (Ervebo®) presented at ECCMID 2023 PR Newswire
12.04.23 - PR Newswire
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-​ZEBOV (Ervebo®) at ECCMID 2023 PR Newswire
03.04.23 - PR Newswire
INOVIO Reports Inducement Grant Under Inducement Plan
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire
03.03.23 - PR Newswire
INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference
INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference PR Newswire
01.03.23 - PR Newswire
INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights
INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights PR Newswire

Newssuche

Videos

newspaper
23.05.24 +2,41%
Technical Trading: Sojabohnen im saisonalen Trend
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »